Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-eligible for Autologous Stem Cell Transplantation (ASCT)”

10 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 10 results

Testing effectiveness (Phase 2)Study completedNCT01523834
What this trial is testing

Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT

Who this might be right for
Diffuse Large B-cell Lymphoma
Fondazione Italiana Linfomi - ETS 35
Testing effectiveness (Phase 2)Study completedNCT00799513
What this trial is testing

Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma

Who this might be right for
Diffuse Large B-cell Lymphoma
IRCCS San Raffaele 48
Not applicableUnknownNCT05218603
What this trial is testing

Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

Who this might be right for
Multiple MyelomaNon-eligible for Autologous Stem Cell Transplantation (ASCT)
PETHEMA Foundation 100
Testing effectiveness (Phase 2)Ended earlyNCT02295722
What this trial is testing

GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma

Who this might be right for
Hodgkin's Lymphoma - Relapsed/RefractoryNon-Hodgkin's Lymphoma - AggressiveFollicular Lymphoma
AHS Cancer Control Alberta 100
Testing effectiveness (Phase 2)Looking for participantsNCT07365306
What this trial is testing

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent High Grade B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Primary Mediastinal Large B-Cell Lymphoma+5 more
City of Hope Medical Center
Testing effectiveness (Phase 2)Study completedNCT02038933
What this trial is testing

Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)

Who this might be right for
Lymphoma. Non-Hodgkin
Bristol-Myers Squibb 121
Testing effectiveness (Phase 2)UnknownNCT04021992
What this trial is testing

GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL

Who this might be right for
Lymphoma, Large B-Cell, Diffuse
Sun Yat-sen University 48
Large-scale testing (Phase 3)Ended earlyNCT03138499
What this trial is testing

Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,

Who this might be right for
Hodgkin's Disease
Bristol-Myers Squibb 23
Large-scale testing (Phase 3)Study completedNCT02763319
What this trial is testing

A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-cell Lymphoma
Incyte Corporation 453
Large-scale testing (Phase 3)Active Not RecruitingNCT02390869
What this trial is testing

Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

Who this might be right for
Lymphoma, Follicular
Fondazione Italiana Linfomi - ETS 128
43